Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 11/07/2025 BST			5-day change	1st Jan Change
438.95 ^DKK	-3.64%		-2.74%	-29.68%

07-11	European stocks down with bank and healthcare drag, US-EU tariffs in focus	RE
07-11	FDA May Fast Track Drug Reviews for Lower US Prices	MT

Health Care Up on Sales Optimism -- Health Care Roundup

Published on 10/06/2025 at 22:43

Health-care companies rose amid sales growth optimism.

Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo Nordisk's weight-loss medication Wegovy over Eli Lilly's rival product, Zepbound, starting next month.

Shares of both obesity drug makers rose sharply as fears that the Department of Health and Human Services would curtail sales of their blockbuster drugs faded somewhat.

Shares of digital-health tracking firm Omada slid as the initial public offering euphoria wore off.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

06-10-25 1742ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ELI LILLY AND COMPANY	793.01USD	+0.30%	+1.58%	712B
NOVO NORDISK A/S	438.95DKK	-3.64%	-2.74%	305B
CVS HEALTH CORPORATION	64.78USD	-1.28%	-3.93%	81.95B

Latest news about Novo Nordisk A/S

European stocks down with bank and healthcare drag, US-EU tariffs in focus	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
NOVO NORDISK : Gets a Buy rating from UBS	07-11	ZD
Wall Street Waits to Hear the Numbers	07-11
Mining, healthcare prop up European shares; US-EU trade talks in focus	07-10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
European shares close at four-week high on banks boost; US trade talks in focus	07-09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	07-09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	07-09	ZD
Europe rises despite new US tariff mayhem	07-09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	07-08	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	07-08	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	07-08	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	07-08	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company